logo-loader
viewAlliance Pharma PLC

Alliance Pharma provides confident assessment of prospects

It also said it hoped to quickly resolve an issue raised by the Competition & Markets Authority

closeup of the desk of a doctors office with a bottle with pills in the foreground and a stethoscope in the background
The company owns and sells prescription drugs. It also has five star brands that are helping drive top-line growth

Alliance Pharma PLC (LON:APH) gave a confident assessment of prospects in an AGM statement and, separately, said it hoped to resolve objections raised by the watchdog over prescription drug pricing.

The AIM-listed firm was one of a number of companies cited in a document called a Statement of Objections issued by the Competition & Markets Authority (CMA). The mention related to the pricing of an anti-nausea treatment called prochlorperazine.

The company pointed out it hadn’t been involved in the distribution or pricing of prochlorperazine, which generated sales last year of £200,000, since it was licensed to Focus Pharmaceuticals in 2013.

“Alliance will review the Statement of Objections in detail and work closely with the CMA to resolve its alleged objections. Alliance strongly condemns anti-competitive practices,” the healthcare group said in a statement to shareholders.

Ahead of its annual meeting on Thursday, chairman David Cook said the group continued to perform well and in line with expectations, with continued growth coming from the business' international “star” brands.

Robust trading has seen the group generate “strong” free cash flow. So, in the absence of acquisitions, the debt-to-EBITDA ratio should fall below two-times during the second half, Cook confirmed.

Quick facts: Alliance Pharma PLC

Price: 79.1 GBX

AIM:APH
Market: AIM
Market Cap: £416.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Alliance Pharma PLC named herein, including the promotion by the Company of Alliance Pharma PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Grant of Options to Directors

1 week, 3 days ago

Notification of Major Holdings

1 week, 4 days ago

Director's Dealing

1 week, 4 days ago

Total Voting Rights

1 week, 6 days ago

Return of Xonvea Licensing Rights

2 weeks, 5 days ago

Total Voting Rights

on 11/05/2019

Director's Dealing

on 10/09/2019

Total Voting Rights

on 10/03/2019

2 min read